Hepatitis B virus (HBV) genome transcription is highly dependent on liver-enriched, metabolic nuclear receptors (NRs). Among others, NR farnesoid X receptor ␣ (FXR␣) enhances HBV core promoter activity and pregenomic RNA synthesis. Interestingly, two food-withdrawal-induced FXR␣ modulators, peroxisome proliferator-activated receptor-␥ coactivator 1␣ (PGC-1␣) and deacetylase SIRT1, have been found to be associated with HBV genomes ex vivo. 
Chronic hepatitis B is a major worldwide health problem, with Ͼ350 million infected individuals at risk of developing cirrhosis and hepatocellular carcinoma (1) . Hepatitis B virus (HBV) replicates in the liver, a central organ for metabolism. There is increasing evidence to suggest that metabolic regulation pathways play a crucial role in the regulation of HBV transcription and replication (2) .
HBV is an enveloped virus with an extremely compact, partially double-stranded DNA genome of 3.2 kb. Following cell entry, the viral genome is transported to the nucleus and repaired to constitute the covalently closed circular DNA (cccDNA). The cccDNA is structured as a minichromosome by associating with cellular histones and X and core viral proteins (HBx and HBc) and serves as a template for viral RNA transcription (3) . Viral gene expression is mainly controlled at the transcriptional level by core, pre-S1, pre-S2/S, and X promoters and 2 enhancer regions (EnhI and EnhII). The core promoter activity, which is modulated by EnhII, plays a major role in HBV life cycle since it governs transcription of both precore and pregenomic RNAs. The precore RNA encodes the precore protein, while 1 These authors contributed equally to this work. 2 Abbreviations: Act3, activator 3; cccDNA: covalently closed circular DNA; EnhI/II enhancer region I/II; FOXO1, forkhead box protein O1; FXR␣, farnesoid X receptor ␣; HBV, hepatitis B virus; HDAC, histone deacetylase; HIV-1, human immunodeficiency virus 1; HNF-4␣, hepatocyte nuclear factor 4␣; LRH-1, liver receptor homolog 1; NR, nuclear receptor; PGC-1␣, peroxisome proliferator-activated receptor-␥ coactivator 1␣; PPAR␣, peroxisome proliferator-activated receptor ␣; RXR␣, retinoid X receptor ␣; SHP, small heterodimer partner the pregenomic RNA has a dual function: it encodes both core and polymerase proteins and is reverse transcribed following its encapsidation. Resulting nucleocapsids are then enveloped and released as new virions or return to the nucleus and increase the cccDNA pool (4) .
Transcription of HBV genes is intensively regulated by nuclear receptors (NRs), which are transcription factors activated by ligands (hormones or metabolic by-products). HBV enhancer and promoter regions are targeted by liver-enriched NRs. Indeed, ectopic expression of either hepatocyte nuclear factor 4␣ (HNF-4␣), peroxisome proliferator-activated receptor ␣ (PPAR␣), liver receptor homologue 1 (LRH-1), or farnesoid X receptor ␣ (FXR␣) is sufficient to initiate HBV transcription and replication in nonhepatoma cell lines (5) (6) (7) (8) . On a physiological level, those NRs are major regulators in metabolism processes occurring in the liver, such as gluconeogenesis, lipid metabolism, and bile acid homeostasis. Those factors are now considered to be involved in the hepatic tropism of HBV (8) .
The activity of those metabolic regulators is modulated by coactivators, corepressors, and epigenetic factors. Among the numerous modulators of NR activity, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1␣) and SIRT1 appear of particular interest regarding HBV infection. PGC-1␣ is a major NR coactivator, which is activated by food withdrawal, cold, and exercise (9) . PGC-1␣ enhances HBV transcription in vitro through HNF-4␣, FXR␣, LRH-1, and PPAR␣ (5, 6) . Moreover, in a murine model, short-term food withdrawal has been shown to increase HBV replication in a PGC-1␣-dependent way, and the protein has been detected on viral genomes in the livers of infected mice following chromatin immunoprecipitation (10) .
SIRT1, a NAD ϩ -dependent deacetylase, is another major sensor of energy metabolism activated by nutrient deprivation that has been identified on HBV minichromosome ex vivo. SIRT1 has been detected in low replicative viral genomes, suggesting that the histone deacetylase activity of SIRT1 may decrease transcription of HBV genes (11) . However, SIRT1 has also been shown to target proteins implicated in HBV core promoter transcriptional regulation, especially PGC-1␣ and FXR␣. SIRT1 deacetylates and activates PGC-1␣ in response to food withdrawal (12) , and SIRT1-induced deacetylation of FXR␣ increases binding of FXR␣ and its partner retinoid X receptor ␣ (RXR␣) onto the promoter of small heterodimer partner (SHP), an FXR␣ target gene (13) . Using primary mouse hepatocytes, Wei et al. (14) showed that in a context of FXR␣ overexpression, the cooverexpression of SIRT1 led to an up-regulation of SHP transcription. This result indicates that SIRT1 is able to increase FXR␣ activity on an FXR␣ target gene (14) .
The aim of the present study was to clarify the effect of SIRT1 on HBV transcription in vitro. We first used a reporter construct, allowing the specific study of the core promoter transcriptional activity. Next, we sought to determine the global effect of SIRT1 on the transcription of different viral RNAs, using transfection of a full-length HBV genome. Moreover, the involvement of PGC-1␣ and FXR␣ on SIRT1 influence was determined using FXR␣ specific ligands as well as silencing and overexpression experiments.
MATERIALS AND METHODS
Chemicals, antibodies, and siRNA GW4064 was obtained from Sigma-Aldrich (St. Louis, MO, USA). SIRT1 activator 3 (Act3; ref. 15 ) was obtained from Cayman Chemical (Ann Arbor, MI, USA). FXR␣ inhibitor CAS936123-05-6 (described in patent WO 2007052843; Takeda Pharmaceutical Co. Ltd., Osaka, Japan) was synthesized by D.R. Antibodies against FXR␣ (sc-13063) and PGC-1␣ (sc-13067) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TBP (TATAbox binding protein; ab6141), and SIRT1 (ab32441) antibodies were obtained from Abcam (Paris, France). Actin antibody was purchased from Sigma-Aldrich. Stealth RNAi duplexes for low-GC negative control (si-ctrl), FXR␣ (GGAGUAUGCUCUGCUUA-CAGCAAUU), PGC-1␣ (GGGCAGAUUUGUUCUUCCACA-GAUU), and SIRT1 (UACAAAUCAGGCAAGAUGCUGU-UGC) were purchased from Invitrogen Life Technologies (Saint-Aubin, France).
Cell culture
Human hepatoma cell lines Huh-7 and HepG2 (HB-8065; American Type Culture Collection, Manassas, VA, USA) and human embryonic kidney cell line HEK293T were maintained at 37°C with 5% CO 2 in Dulbecco's modified Eagle's medium, containing 100 U/ml of penicillin and 100 g/ml of streptomycin, supplemented with 1% HEPES, 1% NEAA, and 10% of a selected batch of fetal bovine serum (PANBiotech, Aidenbach, Germany).
Plasmids
The plasmid pGL2-EN2/CP, which contains a firefly luciferase reporter gene under the control of the HBV EnhII/ core promoter region (nt 1400 to 1902, HBV genome, ayw subtype; GenBank accession no. U95551), has been previously described (16 Circular full-length HBV genomes were obtained as described previously (19) , with some modifications. A complete HBV genome from ayw subtype (GenBank accession no. U95551) was amplified and cloned into the pCMV-␤gal-vector. Following plasmid amplification and purification, the HBV genome was released by EcoRI digestion; 3.2-kb fragments corresponding to the viral genome were recovered by gel purification and then ligated using T4 DNA ligase. The resulting ligation product was precipitated with ethanol and cleaned on a QIAQuick column (Qiagen, Courtaboeuf, France), according to the manufacturer's instructions.
Quantitative RT-PCR analysis of FXR␣ expression
Endogenous expression of FXR␣ was quantified by quantitative RT-PCR analysis. Total cellular RNA was isolated using the RNeasy kit (Qiagen), according to the manufacturer's instructions. Following DNA digestion with Ambion Turbo DNase (Invitrogen Life Technologies), 500 ng of RNA was reverse transcribed using the high-capacity RNA-to-cDNA Master Mix (Invitrogen Life Technologies). cDNAs were then subjected to 30 PCR cycles with FastStart Universal SYBR green PCR master mix with ROX (Roche Applied Science, Penzberg, Germany) using StepOnePlus real-Time PCR systems (Applied Biosystems; Life Technologies, Foster City, CA, USA). The following primers were used for FXR␣: forward, 5=-TGTGAGGGGTGTAAAGGTTTCT-3=, and reverse, 5=-GCCTGTATACATACATTCAGCCA-3=. TBP quantification was used for normalization using the following primers: forward, 5=-CCACGAACCACGGCACTGATTT-3=, and reverse, 5=-CAGTCTGGACTGTTCTTCACTCTT-3=.
Luciferase assays
Transfections for luciferase assays were performed in 24-well plates containing 1 ϫ 10 5 cells using jetPEI (Polyplus Transfection, Illkirch, France), according to the manufacturer's instructions. Transfection mixtures for each well comprised 200 ng of plasmid pGL2-EN2/CP, 20 ng of plasmid pRL-SV40 (Promega, Charbonnières, France), serving as an internal control for transfection efficiency, and 100 ng of expression vectors for FXR␣, RXR␣, PGC-1␣, SIRT1, and H363Y-SIRT1 when indicated. At 24 h post-transfection, FXR␣ and SIRT1 modulators were added as indicated. At 48 h after transfection, firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay system (Promega).
For silencing experiments, 10 pmol of stealth RNAi for control (ctrl), FXR␣, PGC-1␣, and SIRT1 was added to transfection mixtures for each well. Lipofectamine 2000 (Invitrogen; Life Technologies) was used as a transfection agent, according to the manufacturer's instructions.
Western blot analysis
Western blot analysis was performed according to standard techniques. For FXR␣ expression analysis, enrichment in nuclear proteins was performed as follows. Pelleted cells were washed with PBS and disrupted for 15 min on ice in a hypotonic buffer (100 mM HEPES, pH 7.9; 15 mM MgCl 2 ; 100 mMKCl; 1 mM DTT; and 1% Nonidet P-40). Cell lysates were then centrifuged at 10,000 g for 15 min at 4°C. Pelleted nuclei were resuspended in extraction buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM DTT, and 1% Nonidet P-40) and centrifuged at 12,000 g for 15 min at 4°C. Nuclear protein-containing supernatants were recovered and used for further analysis.
Northern blot analysis
Huh-7 or HEK293T cells (3ϫ10 5 ) seeded in 12-well plates were transfected using jetPEI (Polyplus Transfection) with 150 ng of circular full-length HBV genomes, 200 ng of expression vectors for FXR␣, RXR␣, and PGC-1␣ when indicated, and 150 ng of a yellow fluorescent protein (YFP) expression vector used to monitor transfection efficiency. At 24 h after transfection, FXR␣ and SIRT1 modulators were added as indicated. At 24 h after treatment, cells were harvested for viral RNA analysis. Total RNA was extracted using the RNeasy kit (Qiagen). Northern blot analysis was performed as described previously (20) . Briefly, 1 g of RNA per sample was separated on a 1% agarose-formaldehyde gel and transferred onto a positively charged nylon membrane (Roche Applied Sciences) in 10ϫ SCC buffer. Probe synthesis, labeling, and revelation were performed using the DIG System (Roche Applied Sciences), according to the manufacturer's instructions. Primers used for probe synthesis were forward, 5=-CTGAATCCTGCGGACGACCCTTCTC-3=, and reverse, 5=-GGGCAACATTCGGTGGGCGTTCA-3=. Quantification of HBV RNA was performed using ImageJ software (NIH, Bethesda, MD, USA).
RESULTS

SIRT1 enhances FXR␣-induced activation of the HBV core promoter
The effect of SIRT1 activation on HBV transcription was first studied in human hepatoma cell lines Huh-7 and HepG2 and in human embryonic kidney cell line HEK293T by measuring the activity of a luciferase reporter gene under the control of the HBV EnhII/ core promoter region (pGL2-EN2/PC plasmid; ref. 16 ). This region harbors multiple response elements for NRs, in particular, HNF-4␣, PPAR␣, LRH-1, and FXR␣ (Fig. 1) FXR␣ and SIRT1 cooperate to control the activity of the HBV core promoter. Cells were incubated with GW4064, a synthetic FXR␣ ligand, and increasing doses of Act3, a specific activator of SIRT1 (15) . Treatment with Act3 alone did not significantly modify the core promoter activity in any of the 3 cell lines ( Fig. 2A) . As expected, treatment of Huh-7 cells with GW4064 increased the core promoter activity by ϳ10-fold (16) . Combined treatment with Act3 and GW4064 in Huh-7 cells further increased the luciferase activity in a dosedependent manner, up to 25-fold with 20 M of Act3 ( Fig. 2A) . However, treatment with GW4064 alone or in combination with Act3 did not modify the core promoter activity in HepG2 and HEK293T cell lines. Notably, we observed that the magnitude of Act3-induced activation varied significantly with batches of FCS (data not shown). The serum batch that gave the most reliable results was selected to be used for subsequent experiments.
To understand the differences between the 3 cell lines in response to the same treatments, we used RT-PCR to compare the expression of SIRT1, FXR␣, and its coreceptor RXR␣, as well as PGC-1␣, an FXR␣ coactivator, in Huh-7, HepG2, and HEK293T cells. All cell lines expressed SIRT1, RXR␣, and PGC-1␣ mRNAs, while FXR␣ mRNA was detected in Huh-7 cells but not in HEK293T cells, and hardly in HepG2 cells (data not shown). To confirm this result, we performed FXR␣ mRNA quantification in the 3 cell lines by RT-qPCR ( mRNA (Fig. 2B) . FXR␣, thus, might appear as a limiting factor in the two nonresponsive cell lines to SIRT1 and FXR␣ activation. To confirm this hypothesis, we performed FXR␣ complementation in HEK293T (Fig. 2C ) and in HepG2 cells (data not shown). FXR␣ expression restored the capacity of GW4064 and Act3 to activate the core promoter in a dose-dependent manner. Conversely, FXR␣ silencing in Huh-7 cells (assessed by Western blot) led to an ϳ70% decrease in GW4064-induced activation of the core promoter (Fig.  2D) . Treatment with Act3 and GW4064 in si-controltransfected cells led to a 13-fold increase of the core promoter activity, whereas FXR␣ silencing nearly completely abolished the core promoter activation induced by Act3 and GW4064. Thus, SIRT1 activation by Act3 increases the transcriptional activity of the core promoter in FXR␣-expressing cell lines. Altogether, these data suggest that SIRT1 does not directly modulate the core promoter activity but rather acts through downstream factors including FXR␣.
Increase of FXR␣-induced core promoter activity by Act3 is dependent on SIRT1 expression and deacetylase function
There has been controversy regarding the specificity and mechanism of different sirtuin-activating compounds used in experimental studies (21, 22) . In particular, resveratrol, a natural phenol, which is widely used to activate SIRT1, is known to target numerous cellular proteins, in particular, metabolic regulators, and may not directly activate SIRT1. Thus, we wanted to confirm in our model whether the effect of Act3 on HBV core promoter activity was, indeed, SIRT1-dependent, performing silencing experiments of SIRT1 in Huh-7 cells (Fig. 3A) . Interestingly, SIRT1 silencing totally abrogated the FXR␣-dependent Act3 activation of the transcriptional activity, since the core promoter activity was similar in SIRT1-silenced cells treated with either GW4064 or GW4064 and Act3, and also very similar to the basal level induced by FXR␣ activation alone in control cells. These results indicate that Act3-induced increase of the core promoter activity is dependent on the presence and probably the activation of SIRT1.
To determine whether Act3-induced activation of the core promoter required the NADϩ-dependent deacetylase function of SIRT1, a deacetylase-defective mutant of SIRT1 (H363Y-SIRT1) was overexpressed in Huh-7 cells and compared with wild-type SIRT1 (Fig. 3B) . Overexpression of wild-type SIRT1 did not significantly modify the core promoter activity, whether cells were treated with Act3 or not, indicating that the expression level of SIRT1 may not be a critical factor in Huh-7 cells. Strikingly, overexpression of mutant H363Y-SIRT1 completely abolished FXR␣-dependent Act3-induced activation of the core promoter, suggesting that the deacetylase function of SIRT1 is more essential than its expression level in amplifying the FXR-induced HBV core promoter activation.
SIRT1, PGC-1␣, and FXR␣ constitute a regulatory subnetwork controlling the HBV core promoter transcriptional activity
It has been previously shown that PGC-1␣, an essential coactivator of FXR␣, can be directly deacetylated and activated by SIRT1 during the metabolic response to food withdrawal (12) . Moreover, PGC-1␣ is known to amplify FXR␣-dependent activation of the HBV core promoter (5, 6). We, therefore, sought to determine whether PGC-1␣ was implicated in the core promoter activation induced by FXR␣ and SIRT1. Figure 3 . SIRT1 is required for Act3-induced activation of the core promoter. Huh-7 cells were cotransfected with pGL2-EN2/PC, pRL-SV40 and si-ctrl or SIRT1 si-RNA (A) or pGL2-EN2/PC, pRL-SV40 and pCI-neo3xFlag-SIRT1 or pECE-H363Y-SIRT1 (B). At 24 h after transfection, cells were treated with DMSO, 1 M of GW4064, and 20 M of Act3.At 48 h after transfection, cells were harvested, and firefly and Renilla luciferase activities were measured. Results were normalized for transfection efficiency with Renilla luciferase activity and expressed as fold of the DMSO control condition. Proper expression of both wild-type and mutant SIRT1 was verified in transfected cells by Western blot (not shown). Results are presented as means Ϯ se of Ն4 independent experiments. NS, not significant. *P Ͻ 0.03; Student's t test.
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We first overexpressed PGC-1␣ alone or in combination with FXR␣ and RXR␣ in Huh-7 cells treated with GW4064 and Act3 (Fig. 4A) . In the absence of GW4064 and Act3, PGC-1␣ overexpression led to an ϳ15-fold induction of the core promoter activity. This result probably represents the coactivation of endogenous nuclear receptors that control HBV transcription, including FXR␣. Treatment of PGC-1␣-transfected cells with Act3 increased the core promoter activity by ϳ30-fold, indicating that PGC-1␣ may integrate SIRT1 signaling. GW4064 treatment enhanced the core promoter activity by 45-fold, confirming that PGC-1␣ was able to cooperate with FXR␣ to enhance the HBV core promoter activity. Moreover, when PGC-1␣-overexpressing Huh-7 cells were treated with both Act3 and GW4064, the core promoter activity was significantly increased compared with use of Act3 or GW4064 alone. Interestingly, cooverexpression of FXR␣-RXR␣ did not further modify the core promoter activity in the absence of FXR␣ activation by GW4064 but very significantly increased this activity in GW4064 and GW4064-Act3 treatment conditions (by more than 150-fold for the latest condition, compared to control and untreated cells). These data confirmed that PGC-1␣ coactivates FXR␣ in this model and showed that this effect is potentiated by SIRT1 activation.
We then wondered whether PGC-1␣ was necessary for FXR␣ and/or SIRT1 to activate the core promoter. Silencing of endogenous PGC-1␣ expression decreased by ϳ50% the activation of the core promoter induced by treatment with GW4064 or with GW4064 and Act3, while no significant variation was observed for untreated or Act3-treated cells (Fig. 4B) , suggesting that the effect of SIRT1 on FXR␣-induced activation of the core promoter requires the presence of PGC-1␣.
To further understand the interactions between FXR␣, PGC-1␣, and SIRT1 in the activation of the HBV core promoter, we next performed the silencing of endogenous FXR␣ and SIRT1 in Huh-7 cells overexpressing PGC-1␣ (Fig. 4C) . FXR␣ or SIRT1 silencing dramatically decreased PGC-1␣-induced activation of the core promoter by between 56 and 74% and between 53 and 66%, respectively, in cells treated with DMSO, Act3, GW4064, or GW4064-Act3. We also per- formed overexpression of FXR␣, RXR␣, and/or PGC-1␣ in Huh-7 cells treated by Act3 and FXR␣ inhibitor (Fig. 4D) . Treatment by Act3 led to a significant increase of core promoter activity in both overexpression conditions, confirming that FXR␣ expression level may influence SIRT1 activation effect. Moreover, inhibition of FXR␣ activity by the FXR␣ inhibitor resulted in a decrease of Act3-induced activation of the core promoter in cells overexpressing FXR␣, RXR␣, and/or PGC-1␣, meaning that basal activation of FXR␣, probably due to the presence of bile acids in the serum used (data not shown), was responsible for Act3-induced increase of the core promoter activity.
Altogether, these results strongly suggest that PGC-1␣ is involved in SIRT1 and FXR␣-induced activation of the core promoter. Indeed, FXR␣, PGC-1␣, and SIRT1 seem to constitute a subnetwork of interdependent proteins that modulates the HBV core promoter transcriptional activity.
FXR␣/PGC-1␣/SIRT1 subnetwork increases synthesis of HBV RNA
In the context of a whole HBV genome, the core promoter and EnhII regions are not autonomous, but dependent on other transcriptional regulatory sequences, in particular, the EnhI region (23) . Moreover, viral proteins HBc and HBx associate with HBV minichromosomes, and one of them, HBx, has been shown to play a role in modulating cccDNA transcription (11) . We, thus, wanted to examine the effect of FXR␣ and SIRT1 activation in Huh7-cells and HEK293T cells transfected with circular full-length HBV genomes (designated as HBV-transfected cells), which contain every enhancer and promoter sequence and allow synthesis of all HBV proteins. Synthesis of core promoter-controlled 3.5-kb, preS2/S, and preS1 promoter-controlled 2.1/2.4-kb, and X promotercontrolled 0.7-kb viral RNAs was first assayed by Northern blot in Huh-7 cells (Fig. 5A) . Expression of 3.5-kb RNA was significantly induced by GW4064 with or without Act3. Moreover, overexpression of FXR␣, RXR␣, and PGC-1␣ increased synthesis of the 3.5-kb RNA by 2.5-fold in cells treated with GW4064 and by 3.5-fold in cells treated with both FXR␣ and SIRT1 activators, with a statistically significant difference between the two conditions. In the same conditions of treatment, we also observed a parallel increase in synthesis of the 2.1/2.4 kb RNAs. Basal expression level of 0.7-kb X RNA was low but also increased in cells overexpressing FXR␣, RXR␣, and PGC-1␣ and treated with GW4064. However, treatment with Act3 and GW4064 did not significantly modify synthesis of 0.7-kb RNA compared to treatment with GW4064 alone. These results indicate that activation of the FXR␣/ PGC-1␣/SIRT1 axis increases not only 3.5-kb HBV RNA transcription from the core promoter, but also synthesis of 2.1/2.4-kb RNA.
We also performed Northern blot analysis in HEK293T cells in order to evaluate the effect of the FXR␣/PGC-1␣/SIRT1 axis in a cell line that does not express the liver-enriched nuclear receptors that initiate transcription of the HBV 3.5-kb RNAs (Fig. 5B) . As expected, following transfection of HBV genomes, we did not observe any synthesis of viral RNAs, but overexpression of FXR␣, RXR␣, and PGC-1␣ was sufficient to initiate transcription of viral genes. In HBVtransfected HEK293T cells overexpressing FXR␣, RXR␣, and PGC-1␣, synthesis of 3.5-kb RNAs was not significantly modified by treatment with Act3 alone. FXR␣ activation by GW4064 increased the expression level of the 3.5-kb RNA by ϳ3-fold, and combined treatment with both Act3 and GW4064 by ϳ6-fold compared with DMSO-treated cells. As in Huh-7 cells, we observed a parallel increase of 2.1/2.4-kb RNA synthesis in the same conditions of treatment and with nearly the same amplitude. 0.7-kb RNA synthesis was also increased in cells treated with GW4064 and Act3, but to a lower extent. These results, thus, confirm data obtained using the reporter system, even though at a lower level, and indicate that activation of the FXR␣/ PGC-1␣/SIRT1 axis induces transcription of HBV RNA both in hepatoma and nonhepatoma cell lines.
DISCUSSION
In this study, we showed that histone deacetylase SIRT1 participates in the increase of HBV replication dependent on FXR␣ and PGC-1␣ in vitro. All three proteins appear to constitute a subnetwork that modulates HBV promoter activity and viral transcription. This result may appear surprising as, on the basis of the histone deacetylase activity of SIRT1 combined to identification of SIRT1 on low replicative cccDNA ex vivo, it could have been predicted that SIRT1 activation would rather decrease HBV transcription. Indeed, acetylation and deacetylation of histones have been shown to play a major role in the transcriptional regulation of several DNA viruses able to persist in infected cells either as episomes or as integrated genomes, such as members of the Herpesviridae family, HBV, or human immunodeficiency virus 1 (HIV-1) (24, 25) . In particular, inhibition of HDAC has been shown to induce reactivation of a fraction of latent HIV-1 viruses in different experimental models (26) and is now envisaged as a putative new therapeutic agent (27) . The most likely explanation for the SIRT1-induced activation of the HBV core promoter that we observed in vitro is that SIRT1 may preferentially target nonhistone proteins (28) . In particular, SIRT1 is known to deacetylate several transcription factors and transcriptional modulators involved in metabolism regulation, which have been shown to activate HBV transcription. We focused in this study on FXR␣ and PGC-1␣, which have been shown to activate transcription from the HBV core promoter. We observed that Act3-induced SIRT1 activation did not modify HBV transcription when FXR␣ was not activated by its ligand, suggesting that SIRT1 only indirectly modulates HBV transcription via one or several targets. Indeed, in the three cell lines used in this study, FXR␣ expression and activation were necessary to observe maximal induction of the core promoter activity by PGC-1␣ and SIRT1.
Our results show that FXR␣ is an important NR modulating the core promoter activity in vitro. We confirmed that FXR␣, coactivated by PGC-1␣, strongly increases HBV gene transcription. On the basis of FXR␣-silencing experiments, we also showed that FXR␣ was involved in PGC-1␣-induced activation of the core promoter in Huh-7 cells. Interestingly, Wu et al. (29) showed that FXR␣ was the most up-regulated gene among 84 NRs and related genes studied in HepG2.2.15 cells (which contain an integrated HBV genome) compared to parental HepG2 cells, and it has been shown that miR-1, one of the microRNAs involved in hepatocyte differentiation, modulates HBV replication by increasing FXR␣ expression and decreasing histone deacetylase 4 activity (HDAC4, a suppressor of HBV biosynthesis; ref. 30) . Put together, these observations suggest that, among the NRs that are involved in HBV regulation, FXR␣ plays an essential role in hepatoma cell lines. Indeed, the level of endogenous FXR␣ in Huh-7 cells allowed a strong induction of the core promoter activity in response to FXR␣ and SIRT1 activation, whereas FXR␣ overexpression was necessary in HepG2 cells to observe the activation of the core promoter in response to SIRT1 stimulation. Whether SIRT1 can modulate HBV transcription in a way that is strictly dependent on the axis composed of FXR␣ and PGC-1␣, or by targeting other factors, still has to be determined. In particular, SIRT1 has also been shown to modulate other transcription factors and NRs involved in HBV transcription, such as PPAR␣ and Forkhead box protein O1 (FOXO1) (31, 32) . These findings suggest, nonetheless that, when screening for HBV transcription modulators, levels of FXR␣ expression and activation (and those of other metabolic NRs and modulators) have to be determined and taken into account.
Experiments using transfections of a full-length HBV genome confirmed that Act3-induced SIRT1 activation, when combined with FXR␣ activation, increased HBV transcription. However, the level of induction was rather low compared to results obtained using our reporter system. Reasons for this discrepancy are still unclear, but our results suggest that, in the context of a full-length virus, when all viral proteins are expressed, transcription regulation may be regulated by other factors, such as cccDNA-bound viral proteins HBc and/or HBx. Indeed, Belloni et al. (11) have previously identified numerous chromatin-modifying enzymes, such as SIRT1, P300, and histone deacetylase 1 (HDAC1), which are associated with HBV minichromosomes. Among those proteins, recruitment of deacetylases on HBV minichromosomes was enhanced in the absence of HBx. Belloni et al. also observed that, compared to wild-type viruses, HBx-deficient viruses had a decreased histone acetylation and a decrease of pregenomic RNA synthesis and HBV replication, but no change in the cccDNA pool (3). Interestingly, a direct interaction between SIRT1 and HBV X protein has been reported (33) , but its functional significance remains unclear. Another viral protein, HIV-1 Tat, has been shown to target and inactivate SIRT1, which may contribute to T-cell hyperactivation, thus favoring viral replication (34) . Conversely, SIRT1 itself targets Tat and functions as a coactivator of Tat-mediated transactivation by deacetylating K50 in Tat (35) . Like Tat, HBV X protein is able to transactivate transcription partly by modulating the acetylation and methylation status of cccDNA-bound histones, thus regulating viral transcription. It is, therefore, tempting to speculate that SIRT1 deacetylates HBx and modifies HBx-mediated transactivation of HBV transcription or, inversely, that HBx modulates SIRT1 deacetylase activity. Overall, this suggests that examining in more details the interplay between SIRT1, HBx, and transcription factors and modulators, such as FXR␣ and PGC-1␣ will be of great interest.
Results of Northern blot performed in Huh-7 and HEK293T cells transfected with full-length HBV genomes revealed that Act3-induced SIRT1 activation, when combined with FXR␣ activation, also increases synthesis of 2.1/2.4-kb S RNA. This result was somewhat unexpected as no FXR␣ response element has been described to date on either preS2/S or preS1 promoters. Increased synthesis of 2.1/2.4-kb S RNA may be due to either modulation of S promoters by the EnhII/core promoter region, as described previously (36) or to SIRT1-induced activation of PGC-1␣, which is known to also activate synthesis of HBV S transcripts (10) or to an effect of SIRT1 on other NR or transcription factors known to modulate synthesis of S RNAs, such as PPAR␣ (31) .
The main limitation of our study is that it was performed in hepatoma cell lines. Indeed, epigenetic regulation is known to be deregulated during the carcinogenesis process. Moreover, acetylation and deacetylation of target proteins are dynamic processes that evolve in response to environmental stimuli (37) . In particular, SIRT1 expression and activation levels vary according to fed and fasting states, and those natural fluctuations can hardly be mimicked in in vitro cell culture conditions. Thus, the relevance of the FXR␣, PGC-1␣, and SIRT1 axis, both in modulating HBV and metabolic genes, needs to be assessed in more relevant models. In vivo, the only data available regarding the effect of food withdrawal on HBV biosynthesis come from two studies performed in mice, showing conflicting results. In a model using HBV genomes injected to mice, Shlomai et al. (10) showed that short-term food withdrawal (7 h) significantly increases HBV replication in a PGC-1␣-dependent manner. However, using HBV transgenic mice, Li et al. (38) found that prolonged food withdrawal (48 h) only leads to a limited increase of HBV replication. These apparently contradictory results might be explained by profound differences between those two models of HBV infection and the protocols followed, in particular, concerning the duration of food withdrawal. Thus, metabolic studies in HBV transgenic mice should be carefully analyzed and confirmed in more relevant animal models, such as mice with chimeric human livers infected with HBV. Moreover, studies in HBV-infected patients would be of great interest to determine whether HBV viral load fluctuates during nychthemeron and fed vs. unfed states.
